Cargando…
The Inhibitory Effects of Anti-ERC/Mesothelin Antibody 22A31 on Colorectal Adenocarcinoma Cells, within a Mouse Xenograft Model
SIMPLE SUMMARY: The expression of Renal Carcinoma (ERC)/mesothelin is overexpressed in malignancies such as mesothelioma, pancreatic cancer, and ovarian cancer, and molecular-targeted therapies against ERC/mesothelin have been developed to treat them. Recently, it was revealed that ERC/mesothelin is...
Autores principales: | Taniguchi, Gentaro, Kajino, Kazunori, Momose, Shuji, Saeki, Harumi, Yue, Liang, Ohtsuji, Naomi, Abe, Masaaki, Shibuya, Tomoyoshi, Orimo, Akira, Nagahara, Akihito, Watanabe, Sumio, Hino, Okio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9101225/ https://www.ncbi.nlm.nih.gov/pubmed/35565327 http://dx.doi.org/10.3390/cancers14092198 |
Ejemplares similares
-
Possible reversibility between epithelioid and sarcomatoid types of mesothelioma is independent of ERC/mesothelin expression
por: Kojima, Masataka, et al.
Publicado: (2020) -
ERC/mesothelin is expressed in human gastric cancer tissues and cell lines
por: ITO, TOMOAKI, et al.
Publicado: (2014) -
Bisecting-GlcNAc on Asn388 is characteristic to ERC/mesothelin expressed on epithelioid mesothelioma cells
por: Fujihira, Haruhiko, et al.
Publicado: (2021) -
Newly established ELISA for N-ERC/mesothelin improves diagnostic accuracy in patients with suspected pleural mesothelioma
por: Sato, Tadashi, et al.
Publicado: (2014) -
Rat N-ERC/Mesothelin as a Marker for In Vivo Screening of Drugs against Pancreas Cancer
por: Fukamachi, Katsumi, et al.
Publicado: (2014)